Oncology Spotlight: In-Depth with Prof. Keith Kerr on Reflex Testing and Advances in NSCLC

In this episode of the Oncology Spotlight podcast, we are honored to host Prof. Keith Kerr, a Consultant Pathologist at Aberdeen Royal Infirmary and Honorary Professor at the University of Aberdeen. With over 35 years of experience in thoracic pathology, Prof. Kerr is a globally recognized expert in non-small cell lung cancer (NSCLC), particularly in predictive and diagnostic biomarkers, immunotherapy, and personalized medicine. Join us as Prof. Kerr shares his remarkable journey from medical school to becoming a leading pathologist specializing in thoracic oncology. In this insightful conversation, he delves into: His Path to Pathology: Discover what led Prof. Kerr to specialize in thoracic oncology and how a pivotal research project in lung cancer set the course for his distinguished career. Understanding Reflex Testing in NSCLC: Prof. Kerr explains the concept of reflex testing, why it’s essential in the timely and accurate diagnosis of lung cancer, and how it has transformed patient care by ensuring that crucial molecular and biomarker tests are conducted without delay. The Impact of New Treatment Options: Learn how the advent of targeted therapies and immunotherapies for NSCLC has increased the importance of reflex testing and how it’s applied in current clinical practices. Challenges and Contributions to Lung Cancer Guidelines: Prof. Kerr shares his experiences and challenges in contributing to numerous national and international lung cancer guidelines, offering a unique perspective on the evolving standards in lung cancer diagnosis and treatment. Future of Pathology and the Role of AI: Prof. Kerr also discusses the future of pathology training, especially with the integration of new technologies and artificial intelligence in diagnostics, particularly for lung cancer. Whether you're a healthcare professional, a student, or simply interested in the latest advancements in oncology, this episode offers valuable insights into the evolving field of lung cancer diagnosis and treatment.For inquiries, contact us at [email protected] Let's connect: Website: www.oncoassist.com Twitter: https://twitter.com/oncoassist LinkedIn: https://www.linkedin.com/showcase/oncoassist-oncology-decision-support-tool Instagram:https://www.instagram.com/oncoassist/ Facebook: https://www.facebook.com/ONCOassist